Ram Vasudevan Nampoothiri

12PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)HaematologyTransplantation immunologyGene and molecular therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Jan 16, 2026
Late Immune Effector Cell-Associated Hematologic Toxicity After CD19 CAR-T Therapy: Incidence, Clinical Course, and Resource Utilization.

Philippe Giguère, Nicky Akbarian, Connor Prince

|Dec 14, 2025
Eltrombopag in Treating Post-Allogeneic Hematopoietic Stem Cell Transplantation Cytopenias: Efficacy, Response Durability, and Cost Benefit of Early Drug Tapering.

Rawan Al-Omari, Ram Vasudevan Nampoothiri, Ali Sakhdari

|Jun 07, 2025
Allo-SCT in relapsed CBF-AML: rethinking the remission requirement.

Kateryna Fedorov, Sameer Ramesh Melinkeri, Ram Vasudevan Nampoothiri

|Jan 06, 2025
Impact of Day 11 Methotrexate Dose Adjustments due to Mucositis on the Outcomes Following Allogeneic Stem Cell Transplant in the Setting of Anti Thymocyte Globulin (ATG) Based GVHD Prophylaxis.

Vinita Dhir, Connor Prince, David Allan

|Mar 27, 2024
Cell Therapy Transplant Canada (CTTC) Consensus-Based Guideline 2024 for Management and Treatment of Chronic Graft-Versus-Host Disease and Future Directions for Development.

Dennis Dong Hwan Kim, Gizelle Popradi, Kylie Lepic

|Jan 31, 2022
Allogeneic hematopoietic stem cell transplantation in patients with therapy-related hematologic malignancies developing after multiple myeloma.

Ram Vasudevan Nampoothiri, Ivan Pasic, Arjun Datt Law

Pageof 2

Frequent Collaborators

3 joint publications

Rajat Kumar

2 joint publications

Fotios V Michelis

2 joint publications

Ivan Pasic

1 joint publications

Prasanth Balasubramanian